Skip to content
For laboratory research use only · Not for human or veterinary use · Qualified buyers only
Peptides

What Is CJC-1295? DAC versus No-DAC Identity and Documentation

A research-use identity note on CJC-1295: why DAC and no-DAC forms must be labeled separately, with attributed findings from the primary analogue papers.

What Is CJC-1295? DAC versus No-DAC Identity and Documentation

CJC-1295 is a name used for GHRH-analogue research materials. The original overview of this page is explicit that DAC and no-DAC forms must be labeled and studied separately. The useful first questions are analogue design, that terminology, and confirmation of the exact sequence and modification state on the documents that travel with the lot.

Editorial review: 17 November 2026. Prepared by Velnacor Research Desk for research-use communication only. Published findings below are attributed to the cited papers. They are not claims about a Velnacor lot and are not instructions for use in people or animals.

GHRH analogue design

Published CJC-1295 work starts from human growth hormone-releasing factor (hGRF) 1-29, also called GHRH(1-29). Jetté and colleagues synthesized maleimido derivatives of hGRF(1-29), showed that albumin bioconjugates activated the GRF receptor on the anterior pituitary in rats, and identified CJC-1295 as a long-lasting GRF analogue designed to conjugate in vivo to serum albumin (Jetté et al., 2005). That paper is the primary identification of CJC-1295 as a DAC-bearing (drug-affinity-complex) analogue in the rat and biochemical work described there.

A GHRH analogue is not a ghrelin-receptor agonist. Ipamorelin belongs to a different receptor class; see What Is Ipamorelin? and the comparison page CJC-1295 vs Sermorelin vs Ipamorelin. Sermorelin is a name for GHRH(1-29) itself and is not the same material as a DAC-modified analogue.

DAC versus no-DAC terminology

In catalogs, “CJC-1295” is sometimes used both for a DAC-modified analogue and for a related “no-DAC” form (often discussed alongside tetrasubstituted GRF(1-29) analogues). Those are different modification states. A brief, a quotation, a report, and a label should say which form is intended. Shared family language such as “CJC” or “growth-hormone peptide” is not a specification.

The primary papers cited here identify CJC-1295 as the long-acting, albumin-conjugating analogue (Jetté et al., 2005; Teichman et al., 2006). They do not automatically document a no-DAC catalog SKU. If a no-DAC material is being purchased, its own sequence and modification language should appear on the file, and its report should not be borrowed from a DAC lot.

Published endocrine observations — and their limits

Teichman and colleagues reported prolonged stimulation of GH and insulin-like growth factor I (IGF-I) secretion by CJC-1295, described as a long-acting GHRH analogue, in healthy adults (Teichman et al., 2006). That is a published clinical-research pharmacokinetic and endocrine finding. It is not a protocol for laboratory or personal use, it does not provide administration guidance, and it does not describe the lot offered on a current quotation.

Results from a DAC analogue in a clinical-research paper should not be filed under a no-DAC name, and findings from a GHRH analogue should not be transferred to a GHSR agonist.

Confirming sequence, modification, and lot documents

Ask for the exact product name, the presence or absence of the DAC modification, and the report that belongs to the offered lot. What Is a Peptide COA?, How to Read a Peptide COA, Third-Party Peptide Testing, Explained, and lot traceability apply to each form independently.

Velnacor’s catalog lists separate research-material records for CJC-1295 with DAC and without DAC (internal slugs cjc1295-with-dac and cjc1295-no-dac). There is not a standalone public landing page for every catalog name; use the product directory and the COA Library, then confirm the exact form and current-lot documents in the inquiry. For packing at supply scale, see wholesale peptides.

Using a trial shipment to test the name on the documents

A first shipment is a practical way to see whether the form named on the quotation is the form named on the label and the report. Decide acceptance criteria in advance, including the DAC or no-DAC wording you expect to see. A successful trial tests communication and fulfillment. It is not a biological result, and it does not prove that a later lot with a similar family name is the same analogue.

If a quotation bundles a CJC-1295 form with ipamorelin or another secretagogue, review each row on its own terms. Shared freight does not make a GHRH analogue and a GHSR agonist interchangeable. Send the exact form, specification, and box quantity through the inquiry list when you need an order-specific review. How to Evaluate a Peptide Supplier: B2B Checklist is the process page for that brief.

Selected published literature

  1. Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-3058. doi:10.1210/en.2004-1286. PubMed 15817669.
  2. Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. The Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805. doi:10.1210/jc.2005-1536. PubMed 16352683. Cited as published clinical-research observations, not as a use instruction.

Sourcing notes for qualified buyers

Velnacor’s stated supply terms for qualified research and business buyers include: every batch is third-party tested; orders usually ship within 24 hours, subject to stock, documentation review, and destination; trial orders can start from one box of ten vials; parcels lost or damaged in transit are eligible for free reshipment or a refund; and neutral packaging is available when required. Velnacor operates its own production base and has a long-standing supply-chain business.

Those points describe documentation and fulfillment. They do not describe a laboratory or biological outcome. For an order-specific review, send the material name, specification, box quantity, and destination through the inquiry list.

Research-use notice. All Velnacor products are intended strictly for laboratory research use only. They are not drugs, supplements, or food, and are not intended to diagnose, treat, cure, or prevent any disease. Not for human or veterinary use. Purchasers must be qualified researchers. This article is educational content for laboratory and business readers. It does not provide dosing, reconstitution, administration, diagnostic, or treatment guidance.

My inquiry listNo products added yet0